Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PeriGen Inc.

http://perigen.com/

Latest From PeriGen Inc.

‘Femtech’ Evolving Beyond Periods, Pregnancy And Postpartum

Digital female-centric primary and preventive care and fertility support were top-funded women’s health segments in 2021, drawing $668m and $330m in investments, respectively. Going forward, experts anticipate innovation to address unmet needs related to menopause, vaginal microbiome, endometriosis, and other chronic conditions, and surgeries such as hysterectomies and mastectomies.

Commercial Companies

‘Femtech’ Evolving Beyond Periods, Pregnancy And Postpartum: What’s Next In $1.2Tr Women’s Health

Digital female-centric primary and preventive care and fertility support were top-funded women’s health segments in 2021, drawing $668m and $330m in investments, respectively. Going forward, experts anticipate innovation to address unmet needs related to menopause, vaginal microbiome, endometriosis, and other chronic conditions, and surgeries such as hysterectomies and mastectomies.

Market Intelligence Digital Health

2011 Scrip Asia 100 - TeloVac tailwind helps KAEL-GemVax chart a course to market

Being part of a large listed group relieves KAEL-GemVax from the constant fundraising headaches typical of its peers, writes Ian Haydock. This article is part of the 2011 Scrip Asia 100.

Infectious Diseases Cancer

2011 Scrip 100: All to play for as new technologies shake up the vaccines market

New antigen types, novel delivery systems and a shift away from the low-hanging fruit towards more problematic conditions point to healthy prospects in the vaccines space, writes Dr Peter Charlish.

Infectious Diseases Cancer
See All

Company Information

  • Industry
  • Services
  • Services
    • Managed Care, Insurance, Integrated Systems
    • Outcomes Studies
    • Services sold to health care facilities
    • Specialized outpatient services
    • Utilization Review, Claims Processing, Cost Contai
    • Managed Care, Insurance, Integrated Systems
      • Specialized Provider Networks
UsernamePublicRestriction

Register